Skip to content
Tagged COVID-19 Biotechnology SARS-CoV-2 Life Science cancer CORONAVIRUS pandemic
BioXone

BioXone

rethinking future

May 12, 2025
  • About
  • BiotechTodayNews
    • IndiaWeekly Biotech News of India
    • WorldWeekly Biotech News of The World
  • DNA-TalesArticles
    • BiotechnopediaInteresting articles written by BioXone members and associates.
    • Scientists’ CornerArticles from the pioneers of Biotechnology.
    • Cellular CommunicationInterview of greatest researchers’ in the field.
  • Myth-LysisFact Check
  • Signalling PathwayCareer related updates
    • ExaminationsExamination related articles.
    • Job and InternshipJobs and Internship related articles.
  • Courses
  • Contact

Most Viewed This Week

October 17, 2023October 16, 2023

The Corrosion Prediction from the Corrosion Product Performance

1
October 1, 2023September 30, 2023

Nitrogen Resilience in Waterlogged Soybean plants

2
September 28, 2023September 28, 2023

Cell Senescence in Type II Diabetes: Therapeutic Potential

3
September 26, 2023September 25, 2023

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

4
September 25, 2023September 25, 2023

AI Literacy in Early Childhood Education: Challenges and Opportunities

5
September 22, 2023October 1, 2023

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

6

Search Field

Subscribe Now

  • Home
  • BiotechToday
  • Nanoparticles to treat a common type of cancer- neuroblastoma

Children with Autism have underdeveloped gut microbiota

Specific Infections Require Specific Terminators: CAR T-cells

Nanoparticles to treat a common type of cancer- neuroblastoma
  • BiotechToday
  • World

Nanoparticles to treat a common type of cancer- neuroblastoma

bioxone August 3, 2021August 2, 2021

Nandini Pharasi, Jaypee Institute of Information Technology

What is neuroblastoma?

Neuroblastoma is a condition in which malignant cells develop in the adrenal glands, neck, chest, or spinal cords neuroblasts (immature nerve tissue). A gene mutation (change) handed down from parent to kid can develop neuroblastoma. Neuroblastoma is responsible for 8–10% of all malignancies in children and 15% of cancer-related fatalities in children. Chemotherapy is the standard treatment for neuroblastoma patients with advanced illness, followed by surgical resection or radiation. Tumors are more often detected in the abdomen and are caused by particular types of nerve cells. Current treatments like surgery, radiotherapy, and chemotherapy help eliminate the original tumor, but the tumor will often recur at other locations in the body, making treatment much more difficult.

UCL researchers have devised a novel method of delivering medicines that can inhibit cancer-promoting mutations in neuroblastoma. The results in mice demonstrate that using small bubbles to deliver treatments directly to tumor cells decreased tumor development and increased survival. The study, which was published in the journal Worldwide Cancer Research, now opens a unique therapeutic option.

N-Myc as an important tool:

MYCN (N-Myc) is a gene linked to a poor prognosis that is found to be mutant or hyperactive in around 20% of neuroblastoma patients. The gene is involved in cell growth and development and is generally expressed during fetal development. In neuroblastoma cells, MYCN is overexpressed, promoting uncontrolled cell growth and division and preventing cancer cells from dying. N-Myc, a transcription factor belonging to the Myc family, regulates the expression of genes involved in proliferation, cell growth, protein synthesis, metabolism, apoptosis, and differentiation.

UCL researchers have discovered a technique to silence MYCN by directly delivering a form of genetic material known as siRNA to tumor cells. They created nanoparticles, or small bubbles, that target cancers by using leaky blood arteries around the tumor and specific characteristics were seen exclusively on tumor cells. Most of the nanoparticles delivered by injection reach the tumor and successfully inactivate the MYCN gene that causes cancer. The therapy slowed tumor growth and allowed the mice to live longer after they were diagnosed with cancer.

Future possibilities:

  • Professor Stephen Hart, a senior author, stated “These findings suggest that using MYCN siRNA delivered through nanoparticles might be a novel neuroblastoma treatment option. The next stage would be to figure out how to scale up manufacturing to clinical-grade levels and prove that the therapy is safe. We anticipate that this therapy will complement existing treatments by allowing us to pinpoint treatment to these specific tumor locations.”
  •  “Every year, about 100 families in the United Kingdom learn that their child has neuroblastoma,” said Dr. Helen Rippon, CEO of Worldwide Cancer Research.
  • Unfortunately, cancer is frequently discovered at a late stage, necessitating aggressive therapy. Professor Hart is one of our funded cancer researchers, and this significant finding highlights the importance of early-stage discovery research.

The use of new methods, such as nanoparticles, to transport medicine straight to the center of cancer is an exciting topic of research. These new results pave the way for better treatment options and bring hope to patients and their families.

Also read: First interchangeable biosimilar insulin for diabetic patients

References:

  1. Tagalakis, Aristides D., et al. ‘Integrin‐Targeted, Short Interfering RNA Nanocomplexes for Neuroblastoma Tumor‐Specific Delivery Achieve MYCN Silencing with Improved Survival’. Advanced Functional Materials, June 2021, p. 2104843. DOI.org (Crossref), https://doi.org/10.1002/adfm.202104843.
  2. London, University College. Tiny Bubbles Used to Treat Common Childhood Cancer. https://medicalxpress.com/news/2021-07-tiny-common-childhood-cancer.html. Accessed 31 July 2021.
  • The Corrosion Prediction from the Corrosion Product Performance
  • Nitrogen Resilience in Waterlogged Soybean plants
  • Cell Senescence in Type II Diabetes: Therapeutic Potential
  • Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP
  • AI Literacy in Early Childhood Education: Challenges and Opportunities

Share this:

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X

Related

Tagged cancer chemotherapy effective treatment immature kidney cells kidney cancer Malignant tumor MYCN neuroblastoma of neuroblastoma patients oncology Radiotherapy siRNA Surgery Wilms tumor Worldwide Cancer Research

2 thoughts on “Nanoparticles to treat a common type of cancer- neuroblastoma”

  1. Pingback: Specific Infections Require Specific Terminators: CAR T-cells - BioXone
  2. Pingback: Neuroprosthesis – allowing paralyzed people to communicate - BioXone

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Next Post
  • Biotechnopedia
  • DNA-Tales

Specific Infections Require Specific Terminators: CAR T-cells

DNA tales August 3, 2021

Seshadri Dutta, NIIT University Introduction Chimeric antigen receptor (CAR) T-cells are a type of genetically engineered T- cells, modified in order to produce an artificial T-cell receptor that can be further used for immunotherapy. These receptor proteins are engineered in a way that it gives the T-cells the ability to target a specific protein. Following […]

CAR T-cells

Related Post

  • BiotechToday
  • World

Catalase: Antioxidant Treatment for COVID-19

bioxone October 2, 2020October 1, 2020

-Thota Kanishka Rao, Amity University Kolkata Researchers have discovered that a drug, Catalase, might be the solution to the ongoing coronavirus pandemic. Catalase is a naturally occurring enzyme having the potential as a therapeutic drug treat COVID-19 symptom and suppress the replication of the virus inside the body. Catalase is produced naturally and employed by […]

Share this:

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • BiotechToday
  • World

Triple-negative breast cancer & involvement of ncRNAs

DNA tales August 7, 2021August 7, 2021

Shrestha Dutta, Amity University Kolkata A quick rising pattern has been seen in the frequency of breast cancer (BC) with more than 1 million cases diagnosed every year. As per the molecular properties of HER-2, estrogen receptor (ER), ki-67, and progesterone receptor (PR), BC can be further be divided into assorted subtypes, for example, HER-2 […]

Share this:

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • BiotechToday
  • World

Genotype-Tissue Expression (GTEx) project reveals functional large-effect rare variants (RVs) now can be recognized across human tissues

bioxone September 17, 2020September 17, 2020

-Sristi Raj Rai, Amity University Kolkata In the whirlpool of diseases that strike humans, how worthy will it be to pinpoint the origin behind by just using 4 English alphabets that conclude specie’s fate? Hidden in 98% non-coding regions occurring in the large size of 6.4 bn bp human genome, with minor allele frequency (MAF) […]

Share this:

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X

Breaking News

The Corrosion Prediction from the Corrosion Product Performance

Nitrogen Resilience in Waterlogged Soybean plants

Cell Senescence in Type II Diabetes: Therapeutic Potential

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

AI Literacy in Early Childhood Education: Challenges and Opportunities

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

Exogenous Klotho as a Cognition Booster in Aging Primates

Terms and Conditions
Shipping and Delivery Policy
Cancellation and Refund Policy
Contact Us
Privacy Policy